Recursion Pharmaceuticals... (RXRX)
6.67
0.35 (5.54%)
At close: Jan 15, 2025, 10:53 AM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Revenue | 44.58M | 39.68M | 10.00M | 3.41M | 1.71M |
| Cost of Revenue | 42.59M | 48.27M | 9.10M | 63.32M | 45.81M |
| Gross Profit | 1.99M | -8.59M | 896.00K | -59.91M | -44.10M |
| Operating Income | -350.06M | -245.73M | -182.78M | -84.61M | -62.44M |
| Interest Income | 19.12M | 6.25M | 73.00K | 336.00K | 1.74M |
| Pretax Income | -332.13M | -239.48M | -186.48M | -87.01M | -61.88M |
| Net Income | -328.07M | -239.42M | -178.07M | -87.88M | -62.52M |
| Selling & General & Admin | 110.82M | 81.60M | 57.68M | 25.26M | 18.95M |
| Research & Development | 241.23M | 155.70M | 135.27M | 63.32M | 45.81M |
| Other Expenses | -699.00K | -162.00K | -178.00K | -549.00K | -608.00K |
| Operating Expenses | 351.35M | 237.13M | 192.78M | 88.03M | 64.15M |
| Interest Expense | 97.00K | 55.00K | 2.95M | 1.36M | 635.00K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 394.63M | 285.41M | 192.78M | 88.03M | 64.15M |
| Income Tax | -4.06M | -55.00K | -8.40M | 876.00K | 646.00K |
| Shares Outstanding (Basic) | 207.85M | 175.54M | 170.27M | 165.79M | 165.79M |
| Shares Outstanding (Diluted) | 207.85M | 175.54M | 170.27M | 165.79M | 165.79M |
| EPS (Basic) | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| EPS (Diluted) | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| EBITDA | -299.57M | -227.66M | -174.42M | -81.70M | -58.34M |
| Depreciation & Amortization | 24.40M | 19.49M | 9.10M | 4.44M | 3.54M |